Documents | DEA.gov
Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
      • Fee Waiver
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Recibir Actualizaciones
  • Scam Alert
  • Menú Completo
  • English
  • Español

Main Menu

Explore DEA
  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
    • DEA Museum
    • Wall of Honor
    • Contáctenos
  • Recursos
    • Cartels
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas

Documents

Advanced Search

Enter Keywords Below

Filter Results

Select To Narrow Search Results

Document Type

  • Publication (11)
  • DEA Administrator Remarks (1)

Publication Type

  • Intelligence (9)
  • Forensics (2)
  • DEA Administrator (1)
  • Drug Prevention (1)

Drug Name

  • Narcóticos (opioides) (23)
  • Fentanyl (11)
  • Methamphetamine (10)
  • Drugs of Concern (7)
  • Cannabis (5)
  • Marijuana (4)
  • Cocaine (2)
  • Synthetic Opioids (2)
  • Designer Drugs (1)
  • Ketamine (1)
  • Spice/K2, Synthetic Marijuana (1)
  • Steroids (1)
  • Heroin (7)
  • Xylazine (5)
  • Hallucinogen (1)

Topic

  • Forensic Sciences (2)
  • Family (1)
  • Self Help/Personal Growth (1)
Clear All Results
DOCUMENT

CY 2024 Heroin Report

Septiembre 22, 2025
Publication
The United States Drug Enforcement Administration (DEA) Office of Forensic Sciences laboratory system is comprised of eight regional laboratories distributed across the United States. Heroin seizures ranging in weight from residue to multiple kilograms are routinely analyzed in these laboratories. The analytical protocol typically requires the identification of heroin, other...
Septiembre 22, 2025
DOCUMENT

CY 2023 Annual Heroin Report

Septiembre 22, 2025
Publication
The United States Drug Enforcement Administration (DEA) Office of Forensic Sciences laboratory system is comprised of eight regional laboratories distributed across the United States. Heroin seizures ranging in weight from residue to multiple kilograms are routinely analyzed in these laboratories. The analytical protocol typically requires the identification of heroin, other...
Septiembre 22, 2025
DOCUMENT

State and Territory Report on Enduring and Emerging Threats (STREET) (May edition)

Julio 23, 2024
DEA has prepared this product primarily for law enforcement counterparts (state, local and tribal) and public safety and protection officials with a focus on enduring and emerging threats at both the national and regional levels. This report represents what will be the first of regular STREET reports prepared for and...
Julio 23, 2024
DOCUMENT

Statement from DEA Administrator Anne Milgram on the Increase in DEA Fentanyl Seizures Containing Xylazine

Abril 26, 2024
DEA Administrator Remarks
WASHINGTON – DEA first warned the public of a sharp increase in fentanyl seizures containing xylazine in our March 2023 Public Safety Alert . Since that time, xylazine’s growing prevalence in the fentanyl supply continues to make the deadliest drug threat facing this country even deadlier. In 2023, 30% of...
Abril 26, 2024
DOCUMENT

State and Territory Report on Enduring and Emerging Threats (STREET)

Enero 18, 2024
Publication
DEA has prepared this product primarily for law enforcement counterparts (state, local and tribal) and public safety and protection officials with a focus on enduring and emerging threats at both the national and regional levels. This report represents what will be the first of regular STREET reports prepared for and...
Enero 18, 2024
DOCUMENT

Joint Intrepid Laboratory Releases Priority Project: Sourcing Xylazine

Octubre 19, 2023
Publication
INTREPID confirms both liquid veterinary preparations and powdered xylazine are being used to adulterate fentanyl. INTREPID observed chemical markers in xylazine seizures that can assist in determining precursors, synthetic routes, and potentially connecting cases.
Octubre 19, 2023
DOCUMENT

The Growing Threat of Xylazine and its Mixture with Illicit Drugs

Diciembre 21, 2022
Publication
Xylazine, reported as an adulterant in an increasing number of illicit drug mixtures, has also been detected in a growing number of overdose deaths. It is commonly encountered in combination with fentanyl but has also been detected in mixtures containing cocaine, heroin, and a variety of other drugs. However, xylazine...
Diciembre 21, 2022
DOCUMENT

Illicit Opioid Availability in Pennsylvania 2020

Diciembre 30, 2020
Publication
The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The Philadelphia Field Division (PFD) monitors this threat closely, periodically reviewing multiple data indicators, in conjunction with investigative information, to continually assess the threat, then share analytical findings with stakeholders in federal, state, and municipal governments.
Diciembre 30, 2020
DOCUMENT

The 2018 Heroin Signature Program

Septiembre 03, 2020
Publication
The Drug Enforcement Administration (DEA) Heroin Signature Program (HSP) analyzes hundreds of wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.
Septiembre 03, 2020
DOCUMENT

The 2017 Heroin Signature Program Publication

Agosto 11, 2020
Publication
The HSP (Heroin Signature Program) is one essential component of the DEA’s Intelligence Program to identify trends in heroin trafficking and distribution in the United States. The objective of the program is to identify and quantify the chemical components of heroin seized at U.S. ports of entry (POE), all non-POE...
Agosto 11, 2020
Showing 1 - 10 of 13 results

Paginación

  • Current page 1
  • Página 2
  • Siguiente página ›
  • Última página »
  • Quienes Somos
    • Sobre
    • Contáctenos
    • Museo DEA
  • Recursos
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000
Contact the Webmaster